Activity of a Novel 2-Phenoxy Nicotinic Acid Hydrazide sulfonamide against <i>Leishmania tropica</i>

Introduction: Cutaneous Leishmaniasis is an endemic health problem worldwide. The absence of an alternative chemotherapeutic approach to treating Leishmania infection requires urgent attention. So, the laboratory-trial study aimed to determine the activity of a novel 2-Phenoxy Nicotinic Acid Hydrazide sulfonamide against Leishmania tropica. Methods: The different densities (0.2, 1, 5, 25, and 125 μg /ml) of 2-PNAHS and Glucantime (0.2, 1, 5, 25, and 125 μg /ml) were provided and added to parasite cultures. Then, the anti-Leishmania activity of the 2-PNAHS against Glucantime was determined using an in-cell proliferation ELISA, BRDU (Chemiluminescent). Results: According to the results, a dose-dependent decrease was observed in the viability of the Leishmania (L) tropica promastigotes using Glucantime (P&lt;0.05). Administration of different levels of the 2-PNAHS (0.2, 1, 5, 25, and 125 μg /ml) significantly decreased the Leishmania (L) tropica promastigotes (P&lt;0.05). Additionally, a difference was detected in the anti-Leishmania activity of the 2-PNAHS compared to Glucantime and the control group (P&lt;0.05). Conclusion: These results suggest that 2-PNAHS had anti-Leishmania activity better than Glucantime.